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Abstract
The total synthesis of 22-(3-azidobenzoyloxy)methyl epothilone C is described as a potential
photoaffinity probe to elucidate the β-tubulin binding site. A sequential Suzuki-aldol-Yamaguchi
macrolactonization strategy was utilized employing a novel derivatized C1–C6 fragment. The C22-
functionalized analog exhibited good activity in microtubule assembly assays, but cytotoxicity was
significantly reduced. Molecular modeling simulations indicated that excessive steric bulk in the C22
position is accommodated by the large hydrophobic pocket of the binding site. Photoaffinity labeling
studies were inconclusive suggesting non-specific labeling.
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The epothilone class of natural products, typified by epothilone A (1a), epothilone B (1b), and
epothilone C (2), is an extremely cytotoxic family of macrocyclic compounds. Their isolation
from the myxobacterium Sorangium cellulosum was first reported in 1992 by Gerth et al.1 It
is well established that the binding sites on β-tubulin for the epothilones and taxanes overlap.
However, early observations that the epothilones maintained toxicity against paclitaxel
resistant cell lines, in which the resistance arose from tubulin point mutations in the paclitaxel
binding site, suggested that the mode of binding was significantly different.2 As a result, early
attempts to find a shared pharmacophore between paclitaxel and epothilone B were
unsuccessful.3–6 The clinical importance7 of this class of compounds has led to an explosion
of synthetic activity8 –10 and a truly multi-disciplinary effort has culminated in two β-tubulin-
epothilone binding models. The first model is based on combined molecular modeling, NMR,
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and electron-crystallography (EC) data of Zn2+ induced tubulin sheets,11 while the second
model is derived from NMR studies of epothilone bound to unpolymerized α, β-tubulin dimer
in solution.12
In the EC-model the C7 hydroxyl, the C5 carbonyl, and the C3 hydroxyl of epothilone engage
with Arg282 and Thr274 via H-bonds, while the C1 carbonyl interacts with Arg276. The
thiazole ring then forms a hydrogen bond with His227 in the H7 helix. Although they are remote
from the binding site, the residues Gln292 and Ala231 are important in maintaining the correct
conformation of the M-loop and H7 helix, respectively.
The NMR-model supports the interaction between the C7 hydroxyl and Arg282 and Thr274
and further, that this interaction locks Arg276 into position to form a salt bridge with Asp224.
The thiazole and His227 engage in a π–π interaction and are not hydrogen bonded. Finally,
and perhaps most intriguingly, is the involvement of the hydrophobic pocket hosting Phe270,
which is vital for paclitaxel activity and also hosts the methyl group of epothilone B and thus
accounts for its 10-fold increase in activity over epothilone A.
The underlying consensus of both the EC-model and NMR-model is a rigidification and
alignment of the M-loop and the H7 helix, which leads to a conformational change in the α,
β-tubulin dimer. This hypothesis is in agreement with a different overall macromolecular
structure observed between polymerized and unpolymerized tubulin.13
Mammalian brain tubulin, the most abundant and studied of the tubulins, is highly
heterogeneous due to the existence of seven α- and eight β-isoforms and several types of post-
translational modifications. These combinations are responsible for producing greater than 22
bands when mammalian brain tubulin is separated on high-resolution isoelectric focusing gels.
14 Given this complexity there still remains significant advances to be made in the
understanding of microtubule stabilizing agents. Early information on the paclitaxel binding
site was derived through photoaffinity labeling.15–20 More recently discodermolide
photoaffinity labeling studies have been reported.21 However, to date the photolabeling with
epothilone derivatives has remained elusive. Toward this end we have synthesized the C22-
photoreactive derivative 3. We now report the synthesis of 3 and the resulting microtubule
assembly, cytotoxicity studies, and photoaffinity labeling studies.
The synthesis of the C22 analog follows the well precedented aldol/macrolactonization
approach.22 With the known aldehyde 12 in hand we focused our attention on the synthesis of
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the modified C1–C7 fragment 11 (Scheme 1). Starting from the known β-hydroxy ester 4 two
sequential Frater alkylations where carried out. Thus, the β-hydroxy ester 4 was treated with
2 equiv of LDA and the resulting dianion quenched with 1.1 equiv of allyl iodide to give the
anti-allylated compound 5 in 82% yield. The procedure was subsequently repeated and
quenched with MeI to provide the desired anti-methylated product 6 in 66% yield. The free
alcohol was protected as the TBS ether (94%) and the alkene function of 6 was ozonolyzed to
furnish aldehyde 7 (97%). The aldehyde was subsequently reduced and the resulting alcohol
protected as the trityl ether.
The C6–C7 ethyl chain was then introduced by first converting the ester 8 to aldehyde 9 through
a two-step reduction (80%)/oxidation (89%) sequence. The aldehyde 9 was then treated with
EtMgBr and the resulting alcohol (71%) was oxidized to provide ketone 10 in 89% yield.
Finally, the benzyl group was removed and the free primary C1 alcohol reprotected as TBS
ether 11 in preparation for the aldol reaction.23
Accordingly, the C1–C7 fragment 11 was treated with LDA and then the aldehyde fragment
12 was added to give adduct 13 in 38% yield (Scheme 2). The newly formed alcohol function
was protected as the TBS ether (90%) and the C1 primary TBS ether was removed (72%)
subsequently. The resulting alcohol was sequentially oxidized to the aldehyde (98%) and then
to the acid 14 (94%).
The TBS-protecting group on the allylic alcohol 14 was deprotected (96%) and the macrocycle
closed by employing a Yamaguchi macrolactonization to form the core skeleton 15 in 77%
yield. The trityl group was removed with CSA to give the corresponding primary hydroxyl
derivative in 50% yield. Finally, the meta-azidobenzoic acid was converted to the acid chloride
on treatment with oxalyl chloride, which was subsequently reacted with the epothilone
derivative to form photoaffinity adduct 16 in 82%.24 Removal of the TBS groups with TFA
then gave the target compound 3 (Scheme 2).
The microtubule assembly properties and cytotoxicity of the meta-azido analog 3 are
summarized in Table 1. In the microtubule assembly assay the photoaffinity analog 3 was found
to assemble microtubules in a concentration-dependent fashion.25 However, the assembly was
not as rapid and did not reach the same extent as in the presence of epothilone B. Comparison
of the ED50 values shows that 3 is about 20% as effective as epothilone B. Compound 3 is
much less potent against NCI-ADR and MCF-7 cancer cell lines. The very low cytotoxicity
could be due to poor uptake of 3 by the cells.
The labeling studies, carried out on assembled microtubules with 3H-meta-azido analog 3,
demonstrated that irradiation led to incorporation of label into the protein. However,
competition studies showed that although 40 μM epothilone B did not reduce the labeling by
10 μM analog 3, 40 μM paclitaxel was able to displace approximately 50%. These data suggest
that, although analog 3 can promote the assembly of microtubules, it might bind in such a way
that it cannot be displaced by epothilone B or fully by paclitaxel. Another possibility is that
3 is displaced but when it is free in solution and irradiated, it produces reactive intermediates
that react in a non-specific manner with the protein.
Given that we observed microtubule assembly with 3, and that up to 50% of the binding was
inhibited with Taxol, docking studies were conducted to probe tubulin binding modes and
ligand–receptor interactions for analog 3. Figure 1a shows the docked conformation of 3 in the
β-tubulin binding site.11 Figure 1b shows a comparison of the docked configurations of
epothilone B (yellow) and analog 3 (cyan) in the β-tubulin active site. In analog 3, the bulky
22-(3-azidobenzoyloxy)methyl group slightly reorients the hydrophobic C8–C15 portion of
the compound to avoid unfavorable van der Waals interactions with the bulky C22 position.
This relatively minor rearrangement does not significantly disrupt the hydrogen bonding
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network between receptor and the C1–C7 portion of the ligand. However, in analog 3, the
thiazole hydrogen binds to Arg276 rather than to His 227 as is found with epothilone B.
In summary, the photoaffinity analog 3 promotes the assembly of tubulin into microtubules
and the computer modeling studies revealed key ligand-receptor interactions. Specifically,
molecular modeling simulations indicated that excessive steric bulk in the C22 position is
adequately accommodated by the large hydrophobic pocket in the binding site. However, the
non-specific covalent labeling limits the practical utility of this probe for further elucidation
of the β-tubulin binding site.
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(a) Docked configuration (Surflex-Dock, Tripos, Inc.) of 22-(3-azidobenzoyloxy)methyl
epothilone C (3) shown with MOLCAD (Tripos, Inc.) electron density surfaces of the tubulin
active site (1TVK11), onto which hydrogen bond donor and acceptor regions have been
mapped. Red areas represent hydrogen bond donors; blue areas represent hydrogen bond
acceptors; and gray indicates regions in which no hydrogen bonding takes place. Key ligand–
receptor interactions are shown. Hydrogen bonding occurs between the thiazole nitrogen and
one of the amino groups of Arg276; between the C1 carbonyl and the other amino group in
Arg276; between the C5 carbonyl and the Thr274 backbone NH; and between the C7 OH and
backbone carbonyl of Pro272. (b) The overlay of epothilone B (yellow) and 3 (cyan) in the
binding site (PyMOL, 2006 DeLano Scientific LLC). Docking validation was carried out by
comparing the docked configuration of EpoA to experiment (RMSD = 1.575 Å). The pre-
docked conformation of 3 was prepared by modifying the experimental epothilone A structure
and optimizing the resulting geometry using the MMFF94s force field in MOE (Chemical
Computing Group, Inc.).
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Synthesis of C1–C7 fragment.
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Synthesis of arylazide epothilone analog 3.
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Epothilone B 1.0 0.0015 0.0012
3 5.1 (5.1) 1.2 (632) 1.0 (833)
a
ED50 3/ED50 epothilone B is in parenthesis.
b
D50 values for growth inhibition of human breast carcinoma cell line MCF-7. ED50 values for growth inhibition of NCI-ADR, a P-glycoprotein
over-expressing multi-drug resistant human ovarian carcinoma cell line. Cell proliferation assays were performed as previously described. 25
Microtubule assembly assays were performed as described in Ref. 26.
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